Severe Type 2 Diabetes Induces Reversible Modifications of Endothelial Progenitor Cells Which are Ameliorate by Glycemic Control

Background Circulating endothelial progenitors cells (EPCs) play a critical role in neovascularization and endothelial repair. There is a growing evidence that hyperglycemia related to Diabetes Mellitus (DM) decreases EPC number and function so promoting vascular complications. Aim of the Study This study investigated whether an intensive glycemic control regimen in Type 2 DM can increase the number of EPCs and restores their function. Methods Sixty-two patients with Type 2 DM were studied. Patients were tested at baseline and after 3 months of an intensive regimen of glycemic control. The Type 2 DM group was compared to control group of subjects without diabetes. Patients with Type 2 DM (mean age 58.2±5.4 years, 25.6% women, disease duration of 15.4±6.3 years) had a baseline HgA1c of 8.7±0.5% and lower EPC levels (CD34+/KDR+) in comparison to healthy controls (p<0.01). Results The intensive glycemic control regimen (HgA1c decreased to 6.2±0.3%) was coupled with a significant increase of EPC levels (mean of 18%, p<0.04 vs. baseline) and number of EPCs CFUs (p<0.05 vs. baseline). Conclusion This study confirms that number and bioactivity of EPCs are reduced in patients with Type 2 DM and, most importantly, that the intensive glycemic control in Type 2 DM promotes EPC improvement both in their number and in bioactivity.

[1]  K. Boström,et al.  C‐peptide concentration, mortality and vascular complications in people with Type 2 diabetes. The Skaraborg Diabetes Register , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[2]  J. Lekakis,et al.  Effect of aliskiren on circulating endothelial progenitor cells and vascular function in patients with type 2 diabetes and essential hypertension. , 2015, American journal of hypertension.

[3]  Hong Wang,et al.  Hyperhomocysteinemia and Hyperglycemia Induce and Potentiate Endothelial Dysfunction via μ-Calpain Activation , 2014, Diabetes.

[4]  R. Fernandes,et al.  Reduced levels of circulating endothelial progenitor cells in acute myocardial infarction patients with diabetes or pre-diabetes: accompanying the glycemic continuum , 2014, Cardiovascular Diabetology.

[5]  F. Gherlinzoni,et al.  Prognostic Significance of Circulating and Endothelial Progenitor Cell Markers in Type 2 Diabetic Foot , 2014, International journal of vascular medicine.

[6]  M. Małecki,et al.  Number of circulating pro‐angiogenic cells, growth factor and anti‐oxidative gene profiles might be altered in type 2 diabetes with and without diabetic foot syndrome , 2013, Journal of diabetes investigation.

[7]  Kai-HangYiu,et al.  Specific Role of Impaired Glucose Metabolism and Diabetes Mellitus in Endothelial Progenitor Cell Characteristics and Function , 2014 .

[8]  J. McDermott,et al.  Endothelial progenitor cells and cardiovascular disease. , 2014, Journal of stem cells.

[9]  C. Napoli,et al.  Endothelial progenitor cells and human diseases , 2014, Annals of Hematology.

[10]  C. Napoli,et al.  Potential benefits of cell therapy in coronary heart disease. , 2013, Journal of cardiology.

[11]  C. Desouza Does drug therapy reverse endothelial progenitor cell dysfunction in diabetes? , 2013, Journal of diabetes and its complications.

[12]  Ian A. White,et al.  Impaired Endothelial Progenitor Cell Mobilization and Dysfunctional Bone Marrow Stroma in Diabetes Mellitus , 2013, PloS one.

[13]  Hong Li,et al.  Hyperglycaemia exerts deleterious effects on late endothelial progenitor cell secretion actions , 2013, Diabetes & vascular disease research.

[14]  A. Józkowicz,et al.  [Type 2 diabetes mellitus impairs endothelial progenitor cells functions]. , 2013, Postepy biochemii.

[15]  G. Fadini A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications , 2013, Diabetologia.

[16]  W. Marston,et al.  A Randomized, Controlled Pilot Study of Autologous CD34+ Cell Therapy for Critical Limb Ischemia , 2012, Circulation. Cardiovascular interventions.

[17]  C. Napoli,et al.  Glycoxydation promotes vascular damage Via MAPK‐ERK/JNK pathways , 2012, Journal of cellular physiology.

[18]  Hiroshi Yamamoto,et al.  Diabetes alters subsets of endothelial progenitor cells that reside in blood, bone marrow, and spleen. , 2012, American Journal of Physiology - Cell Physiology.

[19]  H. Sritanaudomchai,et al.  In vitro vessel-forming capacity of endothelial progenitor cells in high glucose conditions , 2012, Annals of Hematology.

[20]  C. Siu,et al.  Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus , 2011, Cardiovascular diabetology.

[21]  C. Napoli,et al.  Endothelial progenitor cells as therapeutic agents in the microcirculation: an update. , 2011, Atherosclerosis.

[22]  S. Issaragrisil,et al.  Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control , 2010, BMC endocrine disorders.

[23]  R. Cubbon,et al.  Effects of insulin resistance on endothelial progenitor cells and vascular repair. , 2009, Clinical science.

[24]  C. Napoli,et al.  Functional impairment of hematopoietic progenitor cells in patients with coronary heart disease , 2008, European journal of haematology.

[25]  C. Napoli,et al.  Comparison between total endothelial progenitor cell isolation versus enriched Cd133+ culture. , 2007, Journal of biochemistry.

[26]  M. Tendera,et al.  Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism? , 2007, Heart.

[27]  D. Link,et al.  The number of endothelial progenitor cell colonies in the blood is increased in patients with angiographically significant coronary artery disease. , 2006, Journal of the American College of Cardiology.

[28]  Doris A Taylor,et al.  Circulating endothelial progenitor cells predict coronary artery disease severity. , 2006, American heart journal.

[29]  C. Heeschen,et al.  Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. , 2005, Journal of molecular and cellular cardiology.

[30]  S. Fichtlscherer,et al.  Reduced Number of Circulating Endothelial Progenitor Cells Predicts Future Cardiovascular Events: Proof of Concept for the Clinical Importance of Endogenous Vascular Repair , 2005, Circulation.

[31]  J. Passauer,et al.  PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. , 2005, Atherosclerosis.

[32]  L. Tavazzi,et al.  Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. , 2005, Blood.

[33]  R. Ferrari,et al.  CD34+ and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive Heart Failure , 2004, Circulation.

[34]  C. Napoli,et al.  Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. , 2001, European heart journal.

[35]  J. Waltenberger Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. , 2001, Cardiovascular research.

[36]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.